Literature DB >> 23261499

Neurochemical profiles of some novel psychoactive substances.

Les Iversen1, Simon Gibbons, Ric Treble, Vincent Setola, Xi-Ping Huang, Bryan L Roth.   

Abstract

Fourteen substances from the class of drugs sometimes known as "legal highs" were screened against a battery of human receptors in binding assays, and their potencies as inhibitors of monoamine uptake determined in functional in vitro assays. Thirteen of the test substances acted as inhibitors of monoamine uptake at submicromolar concentrations, including 9 potent inhibitors of the dopamine transporter (DAT), 12 potent inhibitors of the norepinephrine transporter (NET) and 4 potent inhibitors of the serotonin transporter (SERT). Seven compounds acted as submicromolar inhibitors of both DAT and NET, and three substances 1-(benzofuran-5-yl)propan-2-amine (5-APB), 1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one hydrochloride ("naphyrone") and 1-naphthalen-1-yl-2-pyrrolidin-1-ylpentan-1-one hydrochloride ("1-naphyrone") were submicromolar inhibitors of all three monoamine transporters. There was a lack of correlation between results of functional uptake experiments and in vitro binding assays for the monoamine transporters. There was also no correlation between the human behavioral effects of the substances and the results of bindings assays for a range of receptor targets, although 1-(benzofuran-5-yl)propan-2-amine (5-APB), 1-(benzofuran-6-yl)propan-2-amine hydrochloride (6-APB) and 5-iodo-2,3-dihydro-1H-inden-2-amine hydrochloride (5-iodo-aminoindane) exhibited <100 nM affinities for 5HT(2B) and α(2C) receptors. Functional assays revealed that 5-APB and 6-APB were potent full agonists at 5HT(2B) receptors.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261499      PMCID: PMC3582025          DOI: 10.1016/j.ejphar.2012.12.006

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.

Authors:  D L Nelson; V L Lucaites; D B Wainscott; R A Glennon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-01       Impact factor: 3.000

2.  Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats.

Authors:  J Kehr; F Ichinose; S Yoshitake; M Goiny; T Sievertsson; F Nyberg; T Yoshitake
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

3.  Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone.

Authors:  Raul López-Arnau; Jose Martínez-Clemente; David Pubill; Elena Escubedo; Jorge Camarasa
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Interaction of mephedrone with dopamine and serotonin targets in rats.

Authors:  José Martínez-Clemente; Elena Escubedo; David Pubill; Jorge Camarasa
Journal:  Eur Neuropsychopharmacol       Date:  2011-08-06       Impact factor: 4.600

5.  Pharmacological characterization of designer cathinones in vitro.

Authors:  L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines.

Authors:  N V Cozzi; M K Sievert; A T Shulgin; P Jacob; A E Ruoho
Journal:  Eur J Pharmacol       Date:  1999-09-17       Impact factor: 4.432

7.  Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.

Authors:  Xi-Ping Huang; Vincent Setola; Prem N Yadav; John A Allen; Sarah C Rogan; Bonnie J Hanson; Chetana Revankar; Matt Robers; Chris Doucette; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2009-07-01       Impact factor: 4.436

8.  Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro.

Authors:  Stéphane Doly; Emmanuel Valjent; Vincent Setola; Jacques Callebert; Denis Hervé; Jean-Marie Launay; Luc Maroteaux
Journal:  J Neurosci       Date:  2008-03-12       Impact factor: 6.167

9.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

Authors:  Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

Review 10.  Monoamine transporters and psychostimulant drugs.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

View more
  44 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.

Authors:  Amy J Eshleman; Shanthi Nagarajan; Katherine M Wolfrum; John F Reed; Tracy L Swanson; Aaron Nilsen; Aaron Janowsky
Journal:  Psychopharmacology (Berl)       Date:  2018-11-05       Impact factor: 4.530

3.  Methiopropamine and its acute behavioral effects in mice: is there a gray zone in new psychoactive substances users?

Authors:  Fabio De-Giorgio; Sabrine Bilel; Micaela Tirri; Raffaella Arfè; Claudio Trapella; Cristian Camuto; Federica Foti; Paolo Frisoni; Margherita Neri; Francesco Botrè; Matteo Marti
Journal:  Int J Legal Med       Date:  2020-05-01       Impact factor: 2.686

4.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

5.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

Review 6.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

7.  Substituted methcathinones differ in transporter and receptor interactions.

Authors:  Amy J Eshleman; Katherine M Wolfrum; Meagan G Hatfield; Robert A Johnson; Kevin V Murphy; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2013-04-10       Impact factor: 5.858

8.  The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats.

Authors:  Simon D Brandt; Hailey M Walters; John S Partilla; Bruce E Blough; Pierce V Kavanagh; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2020-09-01       Impact factor: 4.530

9.  Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine.

Authors:  Sean B Dolan; Michael J Forster; Michael B Gatch
Journal:  Drug Alcohol Depend       Date:  2017-08-24       Impact factor: 4.492

10.  Pharmacological profile of novel psychoactive benzofurans.

Authors:  Anna Rickli; Simone Kopf; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.